Forge Biologics
Grove City, US · Founded 2020 · Delaware LLC · 3 known investors
Find your way into Forge Biologics
126 people in our graph share verified history with the Forge Biologics team — schools, employers, funds. One of them is your warm intro.
Will Bruneunlockedknows Timothy J. Miller · together at Case Western Reserve University (overlapped)
×10knows the team · via Case Western Reserve University
knows the team · via John Carroll University
Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.
Founders & leadership
Forge Biologics was founded in 2020 by Timothy J. Miller.
TJ
Timothy J. MillerinCofounder, President & CEO2020–2024Timothy J. Miller holds a Ph.D. in Pharmacology from Case Western Reserve University and has over 30 years of experience in scientific research, business development, and clinical operations. He previously served as founding CEO of Abeona Therapeutics, a NASDAQ-listed gene therapy company, and as CEO of Forge Biologics before its acquisition by Ajinomoto in 2023.
Board
MM
Investors · 3
Funding
SEC filings, press & company announcements$250M disclosed across 3 of 4 rounds · 2020–2022
- $90MSeries CSep 2022 · 3 sourcesSource ↗
▶$120MraisedMay 2021 · 13 investors · BiotechnologyRule 506(b)
▶$120MraisedMay 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick CalloriDirector
- Timothy J. MillerExecutive Officer, Director
- Molly BonakdarpourDirector
- Matthew HammondDirector
- Chris GarabedianDirector
- Offering amount
- $120M
- Amount sold
- $120M
- Sales commissions
- $4.3M
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
▶$40MraisedAug 2020 · 2 investors · BiotechnologyRule 506(b)
▶$40MraisedAug 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris GarabedianDirector
- Molly McCartinDirector
- Timothy J. MillerExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jul 2020
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Forge Biologics do?
- Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.
- Who founded Forge Biologics?
- Forge Biologics was founded by Timothy J. Miller in 2020.
- Who are Forge Biologics's investors?
- Forge Biologics's investors include Aisling Capital, Drive Capital, RA Capital.
- How much funding has Forge Biologics raised?
- Forge Biologics has disclosed $250M raised across 3 of its 4 known rounds.
- Where is Forge Biologics headquartered?
- Forge Biologics is headquartered in Grove City, US.